Panagora Asset Management Inc. Makes New $30.70 Million Investment in Medpace Holdings, Inc. $MEDP

Panagora Asset Management Inc. bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 54,664 shares of the company’s stock, valued at approximately $30,702,000. Panagora Asset Management Inc. owned about 0.19% of Medpace as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. AQR Capital Management LLC raised its position in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the last quarter. Wasatch Advisors LP raised its position in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC raised its position in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares during the last quarter. Invesco Ltd. raised its position in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after buying an additional 60,883 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MEDP shares. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and cut their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Barclays cut their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Finally, BMO Capital Markets cut their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $467.08.

Medpace Stock Up 0.0%

Medpace stock opened at $467.50 on Tuesday. The business has a 50-day simple moving average of $455.81 and a two-hundred day simple moving average of $502.82. The company has a market cap of $13.35 billion, a P/E ratio of 29.38, a P/E/G ratio of 2.37 and a beta of 1.18. Medpace Holdings, Inc. has a 52-week low of $294.07 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.